Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C42H53NO15 |
Molecular Weight | 811.8679 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 13 / 13 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)C5=C(C=C6C(=O)C7=C(C(O)=CC=C7)C(=O)C6=C5O)[C@H]1C(=O)OC
InChI
InChIKey=USZYSDMBJDPRIF-SVEJIMAYSA-N
InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+/m0/s1
Molecular Formula | C42H53NO15 |
Molecular Weight | 811.8679 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 13 / 13 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.druginfosys.com/Drug.aspx?drugCode=29&drugName=Aclarubicin%20(HCl)&type=8
Curator's Comment: description was created based on several sources, including:
http://www.druginfosys.com/Drug.aspx?drugCode=29&drugName=Aclarubicin%20(HCl)&type=8
Aclarubicin (INN) or aclacinomycin A is an anthracycline drug is primarily indicated in conditions like Acute non-lymphoblastic leukemia, Breast cancer, Gastric cancer, Lymphoma, Ovarian coma, Small cell lung cancer, Thyroid cancer. Soil bacteria Streptomyces galilaeus can produce aclarubicin. Aclarubicin (HCl) is used in combination with different anticancerous drugs to obtain best therapeutic results and to reduce toxicity or side effects. Aclarubicin (HCl) is administered intravenously. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094255 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23533247 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Sources: http://www.ncbi.nlm.nih.gov/pubmed/3867405 |
Primary | Unknown Approved UseUnknown |
||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation. | 2005 Dec |
|
Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening. | 2009 Mar 24 |
|
Aclarubicin-induced apoptosis and necrosis in cells derived from human solid tumours. | 2010 Jul 19 |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
|
Discovery, synthesis, and biological evaluation of novel SMN protein modulators. | 2011 Sep 22 |
Sample Use Guides
25 to 100 mg/sq.meter. Maintenance, Every 3-4 Week
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2912388
aclarubicin (ACR) blocked the human lymphocytes progression at G1 period at the concentrations of 100 and 200 ng/ml, but the number of dead cells was not increased.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:52:45 GMT 2025
by
admin
on
Mon Mar 31 17:52:45 GMT 2025
|
Record UNII |
74KXF8I502
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QL01DB04
Created by
admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
|
||
|
WHO-ATC |
L01DB04
Created by
admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
|
||
|
NCI_THESAURUS |
C987
Created by
admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
57576-44-0
Created by
admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
|
PRIMARY | |||
|
451415
Created by
admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
|
PRIMARY | |||
|
77980
Created by
admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
|
PRIMARY | |||
|
CHEMBL502620
Created by
admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
|
PRIMARY | |||
|
D015250
Created by
admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
|
PRIMARY | |||
|
260-824-3
Created by
admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
|
PRIMARY | |||
|
C202
Created by
admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
|
PRIMARY | |||
|
100000084625
Created by
admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
|
PRIMARY | |||
|
239
Created by
admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
|
PRIMARY | RxNorm | ||
|
80
Created by
admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
|
PRIMARY | |||
|
74KXF8I502
Created by
admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
|
PRIMARY | |||
|
4945
Created by
admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
|
PRIMARY | |||
|
ACLARUBICIN
Created by
admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
|
PRIMARY | |||
|
74619
Created by
admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
|
PRIMARY | |||
|
SUB05243MIG
Created by
admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
|
PRIMARY | |||
|
DTXSID1022554
Created by
admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
|
PRIMARY | |||
|
m1374
Created by
admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
|
PRIMARY | Merck Index | ||
|
DB11617
Created by
admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
|
PRIMARY | |||
|
208734
Created by
admin on Mon Mar 31 17:52:45 GMT 2025 , Edited by admin on Mon Mar 31 17:52:45 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |